BLU News and Press, BELLUS Health Inc.

Stock-exchange announcement - For media and investors only - GSK completes acquisition of BELLUS Health Canada NewsWire LONDON , June 28, 2023 /CNW/ - GSK plc (LSE: GSK) (NYSE: GSK) and BELLUS Health Inc. (TSX: BLU) NASDAQ: BLU) today announced GSK has completed ...

BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU.TO) (“ BELLUS ” or the “ Company ”) today announced the positive outcome of the BELLUS shareholders (“ Shareholders ”) vote at this morning’s special meeting of the Shareholders (the “ ...

2023-06-09 15:00:43 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...

Special Meeting to be held on June 16, 2023 BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU.TO) (“ BELLUS ” or the “ Company ”) today announced that the Superior Court of Québec has issued an interim order authorizing, among other things, the holding o...

2023-05-12 16:20:13 ET BELLUS Health press release ( NASDAQ: BLU ): Q1 GAAP EPS of -$0.20. Revenue of $3K (-25.0% Y/Y). For further details see: BELLUS Health GAAP EPS of -$0.20, revenue of $3K

- Announced agreement to be acquired by GSK for US$14.75 per share of common stock in cash representing an approximate total equity value of US$2.0 billion and a premium of approximately 103%; transaction expected to close in Q3 2023 – BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU)...

2023-04-27 12:44:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Willy Barton / Shutterstock.com It’s a complicated time for GSK (NYSE: GSK ), formerly known as GlaxoSmithKline. Shares of the U.K. pharmaceutical company...

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“ BELLUS Health ” or the “ Company ”), a clinical-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough, starting with the development of camlipixant (BLU-5937) for the ...

2023-04-26 09:00:00 ET Earlier this month, U.K.-based drugmaker GSK (NYSE: GSK) reached a deal to buy Canadian biotech company Bellus Health (NASDAQ: BLU) for $2 billion in cash. With the acquisition anticipated to close by the third quarter of this year, it's worth aski...

2023-04-24 05:31:06 ET Summary Biotech stocks have been consolidating recently but may be ready to rally higher due to factors such as a declining 10-year yield and growing M&A activity. Biotech deal-making has been increasing, with large acquisitions such as Pfizer's acquisit...